-
Pulmonary toxicity of synthetic amorphous silica – effects of porosity and co...
Materials can be modified for improved functionality. Our aim was to test whether pulmonary toxicity of silica nanomaterials is increased by the introduction of: a) porosity;... -
Enteric-coated budesonide for the induction and maintenance of remission of C...
Objective: These studies evaluated the safety and efficacy of enteric-coated budesonide for the induction and maintenance of remission of mild-to-moderate Crohn’s disease (CD)... -
Additional file 4: Table S3. of Nano-risk Science: application of toxicogenom...
Details of rodent studies considered by NIOSH in calculating points of departure (PODs). (DOCX 15Â kb) -
MOESM1 of Availability, accessibility and delivery to patients of the 28 orph...
Additional file 1: Table S1. Questionnaire addressed to MetabERN centres. Table S2. Responding centres. Table S3. List of the 28 EMA-approved OMPs for HMDs. Table S4. List of... -
Additional file 1 of Development, implementation and user experience of the V...
Additional file 1: Supplementary Table 1. Initial Clinical Performance Measures Identified by the VHA Dialysis Dashboard Committee. -
Crosslinked nanogel-based porous hydrogel as a functional scaffold for tongue...
Surgical resection in tongue cancer can impair speech and swallowing, reducing quality of life. There is a need for biomaterials that can regenerate tongue muscle tissue... -
Additional file 3: of Pancreatic cancer as a sentinel for hereditary cancer p...
Table S4. Is a list of reports/genes used for meta-analysis. Table S5. is the values that were used to create Fig. 3. (DOCX 34 kb) -
dedup_wf_001--571a17694440cf9d7211e5becc8d48f9
Detailed listing of herbal medicines used according to their safety classification. (PDF 1342 kb) -
Additional file 1 of Preparation, characterization and in vitro–in vivo evalu...
Additional file 1: Fig. S1. The survival rate of L02 cells treated by BTZ-NP. Fig. S2. The survival rate of 4T1 cells exposed to blank supermolecular nanovehicles without BTZ.... -
Additional file 1: of Emergence of RAS mutations in patients with metastatic ...
Table S1. The list of activation mutations detected using the MassARRAY system. (DOCX 17 kb) -
dedup_wf_001--e1f87feb76889f6f82af561521dcdf63
Additional file 2: Supplementary Table 2. Level of Agreement with Statements Regarding the VHA Dialysis Dashboard: Subgroup Findings. -
Additional file 1: Table S1. of Phase 1/2 study of pacritinib, a next generat...
Dose adjustment and toxicity management guidelines—non-hematologic toxicities. Table S2 Serious adverse events and deathsa occurring in phase 1 component of the study (n = 43).... -
Additional file 3: of A prospective phase I dose-escalation trial of stereota...
Table S1. Target Dose and Volume Data by Individual Patient. CTV- clinical target volume; PTV-I – initial planning target volume; PTF-F – final planning target volume; NR – not... -
The Safety and Feasibility of Re-treating Patients with Severe Emphysema with...
Severe emphysema patients who have been treated with endobronchial coils have been shown to initially benefit, but slowly decline in the years thereafter. Re-treating a patient... -
Additional file 5: of Epidemiology of taeniosis/cysticercosis in Europe, a sy...
Table S3. Individual taeniosis cases identified in case reports in eastern Europe available from 1990 to 2017. Table S4. Aggregated taeniosis cases reported in documents... -
dedup_wf_001--fdc36703e9917bc63ef98436dece99a0
Table S3. Comparison of adverse events and serious adverse events between the low-dose and conventional-dose groups. (DOCX 19 kb) -
dedup_wf_001--a796cf47b544ac2b5dfb435d8b9f82c9
Study methodology. Table S2. Key inclusion and exclusion criteria. Table S3. Adjusted mean (95 % CI) FEV1 trough and peak responses compared to placebo after 4 weeks of... -
dedup_wf_001--4e2333716f09be81419eafbcd461c840
White blood cells (cells/μL) expressed as mean ± SD at the beginning (V1), after 2 weeks (V2) and after 6 weeks (V3) of intervention in all groups. Table S2 Lymphocyte subsets... -
The modulation of PCSK-9 and GAGs by 10-dehydrogingerdione and pentoxifylline...
: The hypolipidemic effect of 10-DHGD was previously reported owing to its anti-inflammatory and anti-oxidant properties. We further investigated the anti-inflammatory role of... -
Additional file 5: of Characterization and validation of potential therapeuti...
Table S2. Affinity of BK011 and Erbitux (Cetuximab) for EGFR. (DOCX 13Â kb)
